Extreme body mass index and survival in newly diagnosed multiple myeloma patients
Urvi A. Shah, Karissa Whiting, Sean M. Devlin, Rachel Ershler, Bindu Kanapuru, David Jungpa Lee, Sabrin Tahri, Thomas Gwise, Even H Rustad, Sham Mailankody, Alexander M. Lesokhin, Dickran Kazandjian, Francesco Maura, Daniel Auclair, Brenda M. Birmann, Saad Z. Usmani, Nicole Gormley, Catherine R. Marinac, Ola Landgren
Abstract
The majority of established prognostic factors for multiple myeloma (MM) are not modifiable and include cytogenetic abnormalities, beta-2 microglobulin, lactate dehydrogenase, age, and Eastern Cooperative Oncology Group (ECOG) performance status [ 1 , 2 ]. There is a lack of evidence-based clinical interventions available to complement existing treatment modalities to improve prognostic trajectories.
Topics & Concepts
Multiple myelomaBody mass indexMedicineInternal medicineIndex (typography)OncologyComputer scienceWorld Wide WebCancer Risks and FactorsMultiple and Secondary Primary CancersLiver Disease Diagnosis and Treatment